Shanghai Junshi Bioscience Co., Ltd.

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before and after surgery helps people with a certain type of advanced esophageal cancer. About 663 participants will receive either toripalimab plus chemo or a placebo plus chemo. The goal…

This Phase 3 trial tests whether adding the immunotherapy drug toripalimab to the standard targeted therapy lenvatinib helps people with advanced liver cancer live longer. About 530 participants will receive either the combination or a placebo plus lenvatinib. The study is double…

This early-stage study is testing an experimental drug called JS203 in about 104 people with relapsed or refractory B-cell non-Hodgkin's lymphoma, a type of blood cancer. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shrinkin…

This early-stage trial is testing a new drug called JS207 in about 98 people with advanced cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Researchers will also loo…